A Multicenter, Retrospective Study (RE-ENACT 2) on the Use of Razumab™ (World’s First Biosimilar Ranibizumab) in Wet Age-Related Macular Degeneration
Tóm tắt
Từ khóa
Tài liệu tham khảo
Alexandru MR, Alexandra NM. Wet age related macular degeneration management and follow-up. Rom J Ophthalmol. 2016;1:9–13.
Friedman DS, O’Colmain BJ, Muñoz B, Tomany SC, McCarty C. Prevalence of age-related macular degeneration in the United States. Arch Ophthalmol. 2004;4:564–72.
Wong WL, Su X, Li X, et al. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Glob Health. 2014;2:e106–16.
Jaffe GJ, Martin DF, Toth CA, et al. Macular morphology and visual acuity in the comparison of age-related macular degeneration treatments trials (CATT). Ophthalmology. 2013;9:1860–70.
Topal T, Kar T, Yıldırım Y, et al. Evaluation of aflibercept treatment responses in eyes with bevacizumab/ranibizumab-resistant wet age-related macular degeneration. Turk J Ophthalmol. 2017;3:133–7.
Cohen SY, Creuzot-Garcher C, Darmon J, et al. Types of choroidal neovascularisation in newly diagnosed exudative age-related macular degeneration. Br J Ophthalmol. 2007;9:1173–6.
Ferris FL, Fine SL, Hyman L. Age-related macular degeneration and blindness due to neovascular maculopathy. Arch Ophthalmol. 1984;11:1640–2.
Thapa R, Bajimaya S, Paudyal G, et al. Prevalence of and risk factors for age-related macular degeneration in Nepal: the Bhaktapur Retina Study. Clin Ophthalmol. 2017;11:963–72.
Woo JH, Sanjay S, Au Eong KG. The epidemiology of age-related macular degeneration in the Indian subcontinent. Acta Ophthalmol. 2009;3:262–9.
Sivaprasad S, Hykin P. What is new in the management of wet age-related macular degeneration? Br Med Bull. 2013;1:201–11.
Regillo CD. Anti-VEGF maintenance therapy for neovascular AMD. Retina Today. 2014;63–67.
Jaki Mekjavic P, Zaletel Benda P. Outcome of 5-year treatment of neovascular age-related macular degeneration with intravitreal anti-VEGF using “treat and extend” regimen. Front Med (Lausanne). 2018;5:125.
Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;14:1419–31.
Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med. 2006;14:1432–44.
Intas Pharmaceuticals Limited. Intas launches RAZUMAB, globally the first biosimilar to Lucentis® (ranibizumab). https://www.prnewswire.com/in/news-releases/intas-launches-razumab-globally-the-first-biosimilar-to-lucentis-ranibizumab-508383021.html. Accessed 12 Jul 2019.
Sameera VV, Ayachit A, Joshi S, Guruprasad AS. Safety and efficacy of Razumab—the new biosimilar in India: our experience. Kerala J Ophthalmol. 2016;28:180.
Sharma S, Khan MA, Chaturvedi A, RE-ENACT Study Investigators Group. Real-life clinical effectiveness of Razumab® (the world’s first biosimilar of ranibizumab) in retinal vein occlusion: a subgroup analysis of the pooled retrospective RE-ENACT study. Ophthalmologica. 2019;241:24–31.
Sharma S, RE-ENACT Study Investigators Group, Khan MA, Chaturvedi A. Real-life clinical effectiveness of Razumab® (world’s first biosimilar ranibizumab) in wet age-related macular degeneration, diabetic macular edema, and retinal vein occlusion: a retrospective pooled analysis. Int J Ophthalmol Eye Res. 2018;6(4):377–83.
Sharma S, RE-ENACT Study Investigators Group, Khan MA, Chaturvedi A. Real life clinical effectiveness of Razumab® (world’s first biosimilar ranibizumab) in wet age-related macular degeneration: a subgroup analysis of pooled retrospective RE-ENACT study. Int J Ophthalmol Eye Res. 2018;6(2):368–73.
Chong V. Ranibizumab for the treatment of wet AMD: a summary of real-world studies. Eye (Lond). 2016;2:270–86.
Ferro Desideri L, Barra F, Ferrero S, Traverso CE, Nicolo M. Clinical efficacy and safety of ranibizumab in the treatment of wet age-related macular degeneration. Expert Opin Biol Ther. 2019;1–17.
Qi H-J, Li X-X, Zhang J-Y, Zhao M-W. Efficacy and safety of ranibizumab for wet age-related macular degeneration in Chinese patients. Int J Ophthalmol. 2017;1:91–7.
Małgorzata F, Stankiewicz A. Effectiveness of ranibizumab intravitreal injections for exudative age-related macular degeneration treatment: 12-month outcomes. Med Sci Monit. 2011;9:CR485–90.
Querques G, Azrya S, Martinelli D, et al. Ranibizumab for exudative age-related macular degeneration: 24-month outcomes from a single-centre institutional setting. Br J Ophthalmol. 2010;3:292–6.
Lai TYY, Staurenghi G, Lanzetta P, et al. Efficacy and safety of ranibizumab for the treatment of choroidal neovascularization due to uncommon cause: twelve-month results of the MINERVA study. Retina. 2018;8:1464–77.
Silva R, Berta A, Larsen M, Macfadden W, Feller C, Mones J. Treat-and-extend versus monthly regimen in neovascular age-related macular degeneration: results with ranibizumab from the TREND study. Ophthalmology. 2018;1:57–65.
Sharei V, Hohn F, Kohler T, Hattenbach LO, Mirshahi A. Course of intraocular pressure after intravitreal injection of 0.05 mL ranibizumab (Lucentis). Eur J Ophthalmol. 2010;1:174–9.
Freund KB, Hoang QV, Saroj N, Thompson D. Intraocular pressure in patients with neovascular age-related macular degeneration receiving intravitreal aflibercept or ranibizumab. Ophthalmology. 2015;9:1802–10.
Sharma S, Toth CA, Daniel E, et al. Macular morphology and visual acuity in the second year of the comparison of age-related macular degeneration treatments trials. Ophthalmology. 2016;4:865–75.
Guymer RH, Markey CM, McAllister IL, Gillies MC, Hunyor AP, Arnold JJ. Tolerating subretinal fluid in neovascular age-related macular degeneration treated with ranibizumab using a treat-and-extend regimen: FLUID study 24-month results. Ophthalmology. 2019;5:723–34.
Kaiser PK. Prospective evaluation of visual acuity assessment: a comparison of snellen versus ETDRS charts in clinical practice (an AOS thesis). Trans Am Ophthalmol Soc. 2009:311–324.